Targeting Bone Cells During Sexual Maturation Reveals Sexually Dimorphic Regulation of Endochondral Ossification

Heather Fairfield1†, Samantha Costa1,2,3†, Victoria DeMambro1,2, Celine Schott4,5, Janaina Da Silva Martins1, Mathieu Ferron4,5, Calvin Vary1,2,3 and Michaela R Reagan1,2,3

1Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, ME, USA
2University of Maine Graduate School of Biomedical Science and Engineering, Orono, ME, USA
3Graduate School of Biomedical Sciences and School of Medicine, Tufts University, Boston, MA, USA
4Molecular Physiology Research Unit, Institut de Recherches Cliniques de Montreal, Montreal, Quebec, Canada
5Department of Medicine and Molecular Biology Programs of the Faculty of Medicine, Université de Montreal, Montreal, Quebec, Canada

ABSTRACT
In endochondral ossification, chondroblasts become embedded in their matrix and become chondrocytes, which are mature cells that continue to proliferate, eventually becoming hypertrophic. Hypertrophic chondrocytes produce cartilage that is then resorbed by osteoclasts prior to bone matrix replacement via osteoblasts. Although sexually dimorphic bone phenotypes have long been characterized, specific modulation of the growth plate during a critical window in sexual maturation has not been evaluated. Here we report that specific depletion of osteocalcin- (OCN-) expressing cells in vivo during sexual maturation leads to dimorphic bone phenotypes in males and females. At 6 to 8 weeks of age, OCN-Cre;IDTR (inducible diphtheria toxin receptor-expressing) mice were treated with diphtheria toxin (DT) for 2 weeks to deplete OCN+ cells. At the end of the study, long bones were collected for μCT and histomorphometry, and serum was collected for proteomic and lipidomic analyses. Ablation of OCN+ cells in mice leads to consistent trends for weight loss after 2 weeks of treatment. Females exhibited decreased skeletal parameters in response to OCN+ cell ablation treatment, as expected. However, OCN+ cell ablation in males uniquely displayed an expansion of hypertrophic chondrocytes, a widening of the growth plate, and an abnormal “clubbing” anatomy of the distal femur. Following DT treatment, mice from both sexes also underwent metabolic cage analysis, in which both sexes exhibited decreased energy expenditure. We conclude that skewing endochondral bone formation during longitudinal growth has a profound effect on body weight and energy expenditure with sex-specific effects on developing bone. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

KEY WORDS: BONE–FAT INTERACTIONS; CHONDROCYTES; CRE; DIPHTHERIA TOXIN; GENETIC ANIMAL MODELS; GROWTH PLATE; OSTEOCALCIN; OSTEOCYTES

Introduction
Sexual differences in the longitudinal growth of the skeleton during childhood and puberty have long been acknowledged in mammals. In humans, the pubertal growth spurt, growth plate closure, and bone mass accrual in males are primarily under the control of estrogens; however, treatment with dihydrotestosterone (a nonaromatized androgen) also resulted in increased ulnar bone length in prepubertal children. In mice, dynamic histomorphometry has revealed differences in bone formation rates: with a higher bone formation rate in males than in females. Traditionally, androgens (stimulatory) and estrogens (inhibitory) were thought to regulate these dimorphisms; however, testosterone in pubertal males can be aromatized into 17β-estradiol and can therefore signal via the androgen receptor or estrogen receptor (ER) α or β. Multiple studies in mice suggest that these processes are limited temporally with estrogens acting during early puberty in females, and androgens acting during late puberty in males. Additionally, androgens are critical regulators of trabecular bone in males regardless of the presence (or absence) of either aromatase inhibitors or ERα; however, functional studies in females...
underlie the importance of estrogen-ERα signaling in their bone formation.\(^{1,3}\)

Bone develops through two main processes: intramembranous ossification and endochondral ossification. The first process involves differentiation of mesenchymal stem cells (MSCs) into osteoblasts to generate new "woven" bone. The second process involves differentiation of MSCs into prechondroblasts and chondroblasts to form cartilaginous matrix.\(^{10}\) In endochondral ossification, chondroblasts become embedded in their matrix and become chondrocytes, which are mature cells that continue to proliferate, eventually becoming hypertrophic. Chondrocyte differentiation is regulated by a number of factors including Indian hedgehog, FGFs, BMPs, and parathyroid hormone-related peptide. Many of which control MSC commitment through Runx2, Sox9, and the Wnt signaling pathways.\(^{4}\) In addition, multiple studies suggest that estrogen signaling through ERα also modulates endochondral ossification through direct signaling in chondrocytes.\(^{1}\) Studies have shown that the androgen receptor has been detected in mammalian chondrocytes, and that these cells respond to androgen stimulation.\(^{5}\) During endochondral bone formation, chondrocytes produce cartilage that is then resorbed by osteoclasts prior to bone matrix replacement via osteoblasts (OBs). The regulation of osteoclasts is controlled by multiple cell types in the BM niche, by their production of the cytokine RANKL, which stimulates osteoclast differentiation and triggers osteoclast activation, and osteoprotegerin, the RANK decoy. Over the past decade, multiple studies have linked bone cells—and OBs in particular, by way of osteocalcin (OCN) production—to processes such as energy metabolism, reproduction, and beyond.\(^{6-9}\)

To examine the general role of OBs, osteocytes, and hypertrophic chondrocytes during a critical window of longitudinal growth, we used the OCN-Cre;iDTR (osteocalcin-driven Cre recombinase; inducible diphtheria toxin receptor) model to deplete these cell types (which specifically express OCN) in males and females. Previous studies have used this model to specifically delete mature OBs and osteocytes, with daily injections of diphtheria toxin (DT) in either young mice\(^{10}\) or with no description of age or sex used.\(^{11}\) In the present study, we observed a potent effect of DT treatment in OCN-Cre;iDTR mice systemically with differential effects on bone in male mice versus female mice. We propose that skewing endochondral bone formation during longitudinal growth negatively affects animal physiology and health with sex-specific effects on developing bone.

**Materials and Methods**

**Mice**

Transgenic mice carrying OCN-Cre crossed with iDTR-expressing mice, both on a C57BL/6J background, were donated by Dr Scadden’s laboratory (Harvard University, Cambridge, MA, USA) to Dr Ghobrial’s laboratory (Dana-Farber Cancer Institute, Boston), then rederived, bred, and used for experiments at the Maine Medical Center Research Institute (MMCRI; Scarborough, ME, USA). C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). All mice were weaned at 21 days after birth, group-housed thereafter, and fed standard chow (4% fat) and sterile water. All mice used for this study were OCN-Cre\(^{+}\), DTR\(^{-}\)mut/mut to eliminate any potential variability based on genotype. Following genotyping, mice were randomly assigned to each group prior to administration of DT (0.0125 mg/kg as has previously been described)\(^{10}\) or vehicle volume equivalent (sterile PBS). In all experiments, injections were delivered every other day via i.p. injections, with a maximum of three injections per week for 2 weeks, with the exception of the metabolic cage experiments where the duration of dosing was only 1 week. Over this time, body weights were measured and recorded, and overall health status and body conditioning score was monitored throughout the duration of DT treatments. AquaPak HydroGel (clear H\(_2\)O; South Portland, ME, USA) and moistened grain were provided on the bottom of all cages throughout the duration of applicable experiments. All experimental studies and procedures involving mice were performed in accordance with protocols approved by the governing institutional animal care and use committee. Additional details can be found in the Supplemental Methods.

**Static and dynamic bone histomorphometry and histology**

All static and dynamic histomorphometric analyses were performed on femurs and reported according to the criteria established by the ASBMR\(^{12}\) by the Harvard Center for Skeletal Research Histomorphometry Core as has previously been reported.\(^{11}\) Static parameters were measured in the distal femoral metaphysis 0.2 mm below the epiphysial growth plate, using an Osteomeasure image analyzer (Osteometrics, Atlanta, GA, USA).

**Microcomputed tomography and osmium tetroxide**

A high-resolution desktop \(\mu\)CT system (\(\mu\)CT40; Scanco Medical AG, Brütisellen, Switzerland) was used to assess trabecular bone microarchitecture and cortical bone morphology, in the proximal metaphysis and mid-diaphysis of the tibia \((n = 10\) mice). Scans of the entire tibia were acquired using a 10-\(\mu\)m\(^3\) isotropic voxel size, 70-kVp peak X-ray tube potential, 114-\(\mu\)A X-ray intensity, with 200-ms integration time, and were subjected to Gaussian filtration and segmentation. Image acquisition and analysis protocols adhered to guidelines for \(\mu\)CT assessment of bone microarchitecture,\(^{13}\) and were executed as previously described.\(^{14}\) Quantification and visualization of bone marrow adipose tissue (BMAT) was performed as we have previously described,\(^{15}\) utilizing osmium tetroxide stain and \(\mu\)CT. Additional details can be found in the Supplemental Methods.

**Body composition**

Dual-energy X-ray absorptiometry for whole-body composition, excluding the head, was performed on mice immediately following treatments or at the end of the recovery period using PIXI-mus (GE Lunar, Fairfield, CT, USA) as described previously.\(^{16}\)

**Serum lipidomic and proteomic analysis**

Proteomic and lipidomic analyses were performed on mouse sera from blood collected retro-orbitally, similar to what we have previously described\(^{14,16}\) Lipidomic and proteomic analyses were completed using a 5600 TripleTOF mass spectrometer (Sciex, Framingham, MA, USA). Downstream analyses, including \(t\) tests and principal component analyses, were completed for both data sets using Sciex MarkerView software, essentially as has been described.\(^{17}\) Lipids were analyzed using a global, bias-free lipid-profiling acquisition technique (MS/MS\(^{[MS]}\)) as has previously been described.\(^{14}\) Protein profiling of blood sera.
was completed with sequential window acquisition of all theoretical spectra using a data-independent method,\(^{(16)}\) and was analyzed using a mouse-specific ion library, which employs multiple fragment ion chromatograms for each protein's tryptic peptides. To identify lipids and proteins that were significantly different between DT-treated animals without recovery and all others, a cut-off of \(p \leq 0.05\) was used; minimal cut-offs for signal intensity were set at \(\geq 100\) for lipid and \(\geq 10,000\) for protein. Proteins found significantly upregulated in DT-treated mice without recovery, when compared with all other groups, were determined via \(t\) test \((p < 0.05)\). Mouse gene symbols for overexpressed proteins were entered into the PANTHER (Protein ANalysis Through Evolutionary Relationships) database for pathway analysis.

Serum-collection methods for chemistry panel
Male and female mice were euthanized through CO₂ inhalation. Immediately following, approximately 1 mL of blood was collected through a cardiac puncture, placed at room temperature for 1 hour to induce clotting, and centrifuged at 153rcf for 15 min to separate serum from cells. A minimum of 270 μL of serum was collected per sample. The samples were processed by the University of Michigan, Ann Arbor, as part of the National Mouse Metabolic Phenotyping Center program of the National Institute of Diabetes and Digestive and Kidney Diseases.

Carboxylated and total mouse OCN ELISA
Carboxylated (Gla) and total mouse OCN were measured in serum collected before and 1 or 2 weeks after administration of DT, using two specific ELISA assays as has been previously described.\(^{(16)}\) Briefly, 96-well ELISA plates (R&D Systems, Minneapolis, MN, USA) were coated with 100 μL of anti-Gla-OCN (2 μg/mL) or anti-Mid-OCN (1.5 μg/mL) diluted in 1X antibody coating buffer (Immunochemistry Technologies, Bloomington, MN, USA) and incubated overnight at room temperature. Afterwards, 2 μL of standard (synthetic Gla-OCN) or diluted serum samples (1:10 dilution in assay diluent) in 98 μL of assay diluent was added, and the plates sealed and placed overnight at 4°C. The next day, the plates were washed five times with 1X Tween and 3% BSA in PBS) for 4 hours at room temperature. Afterwads, 2 μL of standard (synthetic Gla-OCN) or diluted serum samples (1:10 dilution in assay diluent) in 98 μL of assay diluent was added, and the plates sealed and placed overnight at 4°C. The next day, the plates were washed five times with 100 μL of horseradish peroxidase-conjugated anti-CT-OCN (C-terminal region of osteocalcin) (1 μg/mL in assay diluent) was added to each well and incubated on a shaker (~200–300 rpm) for 1 hour at room temperature. Following six washes, detection was performed with 100 μL of tetramethylbenzidine (1-Step Ultra TMB ELISA; Pierce, Rockford, IL, USA) for 15 minutes. The reaction was stopped with 100 μL of HCl 1M and the optical density of each well was determined using a microplate reader set at 450 nm. Concentrations of Gla-OCN and total OCN in the serum samples were calculated from polynomial second-order standard curve obtained from the standard.

Analyses of serum RANKL and SOST
Mouse RANKL and sclerostin (SOST) were measured in serum collected before or at 1 week after administration of DT, using the mouse RANKL ELISA kit (TNFSF11; ab100749) from ABCAM (Cambridge, UK) or the mouse/rat SOST ELISA kit (M5ST00) from R&D Systems according to the manufacturers’ instructions.

Immunohistochemistry labeling of femoral bone sections
SOST protein was labeled in fixed and decalciﬁed, parafﬁn-embedded femoral bone sections as has been previously described\(^{(19)}\) (1:50; SOST primary antibody; biotinylated anti-SOST [BAF1589]; R&D Systems).

Metabolic cages
Female and male mice aged to 6 to 8 weeks were administered vehicle or DT on days 0, 2, 4, and 6. On day 7, mice were weighed and transferred to the Promethion Metabolic Cage System (Sable System, North Las Vegas, NV, USA) in the Physiology Core of MMCRI. Metabolic cage analysis was performed as has been previously described.\(^{(21)}\) Briefly, mice were acclimated in the cages for 24 hours prior to 72 hours of data collection with MetaScreen (Promethion, North Las Vegas, NV) v2.3.15.11. All data presented within are the 24-hour averages of that 72-hour period unless otherwise noted. All raw data generated for each mouse were processed using ExpeData version 1.9.27 (Sable System).\(^{(21)}\)

Statistical analysis
All data are expressed as mean ± SD on the mean unless otherwise noted. Student’s \(t\) test, and ordinary one-way or two-way ANOVA tests were used to determine significance, using \(p < 0.05\) as the cut-off, with Tukey’s multiple comparison post hoc testing unless otherwise noted. GraphPad Prism 6.02 software (GraphPad Software, La Jolla, CA, USA) was used to compute all statistical calculations unless otherwise noted. To query possible correlations between body composition and energy expenditure, ANCOVA analysis was performed using JMP software (SAS Institute, Cary, NC, USA).

Results
OCN+ cell depletion by DT treatment reduces trabecular bone in females and induces cartilage and mineralized tissue expansion of the primary spongiosa in males
We began with a thorough examination of the bone phenotypes in DT-treated OCN-Cre;DTR female mice by femoral histomorphometry. As expected, DT-treated female mice exhibited significantly decreased numbers of osteocytes (Fig. 1A; Supplementary Fig. S1A), confirming the targeting of OCN-expressing cells. However, no significant effects on OBs were observed (Fig. 1B; Supplementary Fig. S1B), perhaps because the total bone surface and bone perimeter were also decreased. DT treatment had no significant effect on osteoclast surface (Fig. 1C; Supplementary Fig. S1C) or osteoid surface per bone surface (Fig. 1D) or on BMAT (Supplementary Fig. S1D). Importantly, targeting osteocytes resulted in significantly reduced femoral trabeculae in overall volume and number (Supplementary Fig. S1EF) with increased trabecular spacing (Supplementary Fig. S1G).

Female tibial bone parameters were then assessed by μCT (Fig. 1E; Supplementary Fig. S1H); the tibial responses were consistent with the aforementioned femoral histomorphometry measurements. DT treatment altered the trabecular bone morphology in these female mice, as evidenced by significantly reduced trabecular bone volumes (Fig. 1F). Moreover, DT-treated females exhibited significantly reduced trabecular BMD (Fig. 1G) and trabecular number (Fig. 1H), as well as increased trabecular spacing (Fig. 1I), with no significant change in trabecular thickness (Fig. 1J). Females also exhibited significantly reduced...
cortical porosity (Fig. 1K), with no significant change in cortical thickness (Fig. 1L) or cortical, total cross-sectional, or marrow area (Supplementary Fig. S1I–K). Collectively, these data suggest that DT treatment in female OCN-Cre;iDTR mice results in reduced trabecular bone parameters with specific reduction of osteocytes.

Fig 1. Legend on next page.
Having observed the expected bone phenotype in female DT-treated mice, we anticipated consistent loss of bone in both sexes; however, this was not the case for male DT-treated OCN-Cre;iDTR mice. In 9 of 12 DT-treated males, we observed an abnormal phenotype within the primary spongiosa in the region of interest for histomorphometry, but because of this, the standard skeletal parameters, which are assessed adjacent to the femoral growth plate, could not be quantified. The three remaining mice exhibited no significant differences according to static histomorphometry (Supplementary Fig. S2A–D). DT treatment resulted in a wide variety of trabecular bone changes in these male mice, as can be seen in the tibial μCT images (Fig. 2A; Supplementary Fig. S2E,F), but there were no significant differences in trabecular bone volume (Fig. 2B), BMD (Fig. 2C), trabecular number (Fig. 2D), or trabecular spacing (Fig. 2E). Interestingly, we detected a significant increase in trabecular thickness (Fig. 2F), although this was varied. Consistent with the characterization in females, males also exhibited significantly reduced cortical porosity (Fig. 2K), with no differences in cortical, total cross-sectional, or marrow areas (Supplementary Fig. S2J–L). These findings show a difference in the DT-induced bone phenotype in OCN-Cre;iDTR males compared with females.

To further investigate the abnormal phenotype observed in males, first we confirmed that OCN+ cells were being targeted by the DT treatment by performing an analysis of serum OCN levels throughout the duration of the DT treatment. We observed significantly lower levels of both total (Fig. 2H) and carboxylated (Fig. 2I) OCN in male DT-treated mice, beginning after only 1 week of DT treatment and maximized at the end of the 2-week injection period. Significantly reduced amounts of OCN confirmed that OCN-producing cells were being targeted by our DT-inducible model in males regardless of the absence of reduced bone.

We next more thoroughly characterized the bone phenotype observed in male mice by exploring if the changes in the growth plate observed in μCT could be related to cartilage. Safranin O staining of femoral sections confirmed normal trabecular bone and growth plate in vehicle-treated males (Fig. 3A,B); however, DT-treated male femurs contained large amounts of uncalcified hypertrophic chondrocytes and widened growth plates (Fig. 3C–E, Supplementary Fig. S3), as well as an expansion of calcified matrix, which was consistent with images and trends detected via tibial μCT. We also observed gross morphological phenotypic differences in DT-treated males compared with vehicle-treated with a surrounding or “clubbing” of the distal femora (Fig. 3F,G), suggestive of osteopetrosis and a lack of RANKL in these mice. To specifically examine the hypothesis that RANKL was aberrantly expressed in this model, we assessed circulating RANKL levels in the serum of DT-treated males after 1 week of treatment. We observed no significant differences in RANKL levels between the treatment groups by RANKL ELISA (Supplementary Fig. S3D).

In the females, we did not observe these effects (clubbing, hypertrophic chondrocytes, or expansion of calcified matrix), although safranin O staining did show some abnormalities at the growth plate, but to a much smaller extent than in males (Supplementary Fig. S4A). Von Kossa staining with safranin O counterstain confirmed the cartilage expansion originating from the growth plate was unmineralized, and there was an increase in mineralized trabecula-like bone throughout the marrow cavity in DT-treated male mice (Supplementary Fig. S4B). The increase in this disorganized, mineralized matrix and excess cartilage in the male mice is suggestive of increased chondrocyte differentiation followed by endochondral ossification, which seems to be occurring in males, but not females.

OCN+ cell removal results in weight loss and alters serum lipid and blood chemistry

Although we observed sex-related phenotypical differences in bone in response to DT, we observed a consistent effect on body composition in both sexes. Indeed, 2 weeks of DT treatment resulted in significant weight loss (Fig. 4A) in both females (Supplementary Fig. S5A) and males (Supplementary Fig. S5B), and nonsignificant trends toward reduced lean mass (Fig. 4B; Supplementary Fig. S5C,D) and fat mass (Fig. 4C; Supplementary Fig. S5E,F). These trends in body composition remained insignificant with normalization to body weight (data not shown). We next performed a large screen to characterize changes in circulating lipids (Table 1). Thirty-six lipids were differentially represented in the sera of DT-treated versus vehicle-treated animals. Overall, there was a decrease in lipid storage species, including triacylglycerides (Fig. 4D) and diacylglycerides (Fig. 4E), as well as sphingomyelins (Fig. 4F), in response to DT, and a general increase in glycerophospholipids (Fig. 4G), including signaling lipids, specifically phosphatidylinositol.

Having observed changes in serum lipids and in response to DT treatment, we used standard blood chemistry to monitor the overall health of the animals. Full blood chemistry analysis revealed varying creatine phosphokinase (CPK) levels in both females (Fig. 4H) and males (Fig. 4I) after targeting bone cells. In the females, CPK levels were significantly elevated in the DT-treated mice compared with vehicle-treated controls (Fig. 4H); however, CPK levels in males were significantly decreased (Fig. 4I). Females also showed an elevation of the liver enzyme, alanine aminotransferase (ALT; Fig. 4I); no such change was observed in males.

**Fig 1.** Diphtheria toxin (DT) treatment in osteocalcin-driven Cre recombinase; inducible diphtheria toxin receptor (OCN-Cre;iDTR) mice depletes osteocytes and reduces trabecular bone in female mice. (A) Quantification of bone via femoral static histomorphometry confirmed significantly reduced osteocyte numbers (osteocyte number per bone area [Ot.N/B.Ar], #/mm²). With no detectable effects on (B) osteoblast (Ob.S/BS, %), (C) osteoclast (Oc.S/BS, %), or (D) osteoid surface (OS/BS, %) per bone surface. Static histomorphometry data represent 8- to 10-week-old female mice: vehicle, n = 14; DT-treated, n = 9. (E) Representative sagittal μCT images of tibial cross sections from vehicle (top) and DT-treated (bottom) mice. Quantification of bone via tibial μCT revealed (F) significantly reduced trabecular bone volume per total volume (Tb.BV/TV, %), (G) reduced BMD, (H) fewer trabeculae (trabecular number [Tb.N], 1/mm), (I) with increased spacing (Tb.Sp, mm) and (J) no change in trabecular thickness (Tb.Th, mm). (K) Cortical porosity (%) was significantly reduced in DT-treated females, (L) with no significant difference in cortical thickness (Ct.Th, mm). Tibial μCT data represent 8- to 10-week-old female mice: vehicle, n = 14; DT treated, n = 11. **p < .05; ***p < .01; ****p < .001; *****p < .0001 versus vehicle. Data shown as individual dot plots ± SD. All analyses were performed as a Student’s t test with GraphPad Prism.
Fig 2. Diphtheria toxin (DT) treatment in osteocalcin-driven Cre recombinase; inducible diphtheria toxin receptor (OCN-Cre;iDTR) male mice induces varying effects on trabecular bone and the expansion of calcified primary spongiosa. (A) Representative sagittal μCT images of male tibias from vehicle (top) and DT-treated (bottom). Quantification of bone via tibial μCT revealed no significant differences in (B) trabecular bone volume per total volume (Tb.BV/TV, %). (C) BMD, (D) trabecular number (Tb.N, 1/mm), or (E) trabecular spacing (Tb.Sp, mm). However, in male mice there was (F) a significant increase in trabecular thickness (Tb.Th, mm) and (G) reduced cortical porosity (%) in DT-treated males. Tibial μCT data represent 8- to 10-week-old female mice: vehicle, \( n = 11 \); DT-treated, \( n = 12 \). Reduced levels of serum total (H) and carboxylated (I) OCN as assessed via ELISA confirm the removal of OCN+ cells over time with DT injections (\( n = 6 \)). *\( p < .05 \); **\( p < .01 \); ***\( p < .001 \); ****\( p < .001 \) versus vehicle. Data shown as individual dot plots ± SD. All analyses were performed as a Student’s t test or one-way ANOVA with GraphPad Prism.
Serum proteomics revealed segregation of samples between vehicle-treated and DT-treated animals by PCA based on analysis of all detectable proteins (Fig. 5A; Table 2). In total, 392 proteins were significantly different ($p < .05$) between DT-treated and vehicle-treated animals, with 145 of them meeting the abundance cut-off for proteomic analysis. Extracellular matrix protein 1 (ECM1) was elevated 3.62-fold in DT-treated animals (Fig. 5B; Table 2), whereas palatin-like phospholipase domain-containing.

**Fig 3.** Diphtheria toxin- (DT-) treated males showed hypertrophic chondrocytes with cartilage expansion into the primary spongiosa after osteocyte ablation. (A) Vehicle-treated males ($\times 4$) showed normal safranin O staining (red), representative of cartilage, along the growth plate. (B) Zoomed-in section ($\times 40$) along the growth plate showed relatively normal chondrocyte size in the vehicle-treated males; scale bar = 50 μm. (C) DT-treated males ($\times 4$) showed increased cartilage expansion into the primary spongiosa. (D) Zoomed-in image ($\times 40$) along the growth plate showed hypertrophic chondrocytes along the growth plate; scale bar = 50 μm. (E) Zoomed-in image ($\times 20$) showed increased cartilage expansion with the presence of hypertrophic chondrocytes throughout the primary spongiosa; scale bar = 100 μm. DT-treated males exhibit an abnormal clubbing phenotype of the distal femur. Representative histology images of the vehicle-treated males illustrate the normal distal femoral phenotype (F) compared with the DT-treated males (G). Images were taken at $\times 4$ magnification. Scale bar = 0.25 mm. Green arrows indicate abnormal region of hypertrophic chondrocytes and cartilage extending from the growth plate. Black arrows indicate a rounding or “clubbing” anatomic change in male femura.
Fig 4. Legend on next page.
Table 1. Top 10 Differentially Expressed Lipids in DT-Treated Sera

| Lipid peak name | p Value | DT to vehicle (fold-change) |
|-----------------|---------|----------------------------|
| HexCer 40:1:2 (LCB 18:1:2-2H2O,LCB 18:0:3-3H2O) | 2.82E-05 | 0.533239958 |
| GM1 42:4:2 (LCB 18:1:2-2H2O,LCB 18:0:3-3H2O) | .0018 | 5.87164266 |
| PE 36:2 (FA 18:1) | .011 | 10.3767816 |
| PC 36:1:2 + HCOO (LPC pe) | .00291 | 2.026539759 |
| CL 84:0 (PS,CL,PIP2,PIM3) | .00299 | 2.566257981 |
| HexCer 40:2:3 (LCB 18:1:2-2H2O,LCB 18:0:3-3H2O) | .00467 | 5.49910319 |
| CL 88:3 (FA 18:0) | .00585 | 2.364392893 |
| HexCer 42:2:2 (LCB 18:1:2-2H2O,LCB 18:0:3-3H2O) | .00674 | 6.07829687 |
| SM 32:2:3 (SM) | .00899 | 7.45250593 |
| SM 42:1:2 (SM) | .00918 | 7.01738286 |

DT = Diphtheria toxin.

protein 2 was significantly decreased in these samples (Table 2). Within the 145 aberrantly expressed proteins included in our analysis, 117 were connected in our network analysis (STRINGv11.0; Fig. 5C) with significant enrichment of proteins involved in critical processes such as membrane trafficking and intracellular transport and translation. Interestingly, we also observed enrichment of proteins associated with nitrogen-containing metabolic processes and lipidprotein metabolism. These findings suggest that targeting bone cells in both sexes has similar systemic effects in modulating body composition and serum composition, but induces sexually dimorphic responses in skeletal phenotypes and blood enzymes.

OCN+ cell depletion results in reductions in energy expenditure in mice

To investigate the relationship between skeletal and overall systemic health, mice were subjected to metabolic cage analysis. DT-treated females exhibited significant decreases in energy expenditure (EE; Fig. 6A). An ANCOVA analysis revealed lean mass to be a significant covariate (data not shown); however, the differences in EE remained significant when the variation in lean mass was taken into account between the two groups (Supplementary Fig. S5D). Resting energy expenditure (Fig. 6B) was also found to be reduced, suggesting the decreases in EE noted above were not caused by reductions in overall activity. Indeed, analysis of EE during levels of peak activity were found to be significantly lower as well (Fig. 6C), further indicating that the decreased EE noted in DT-treated females was independent of activity. No significant changes in respiratory quotient or food consumption were noted (Fig. 6D,E); however, DT-treated females consumed significantly less water across all cycles (Fig. 6F). In addition, females exhibited reductions in the distances run on the wheel (Fig. 6G) and the speed at which they ran (Fig. 6H) following DT treatment. Analysis of the 12-hour cyclic data revealed that the greatest decrease in wheel activity was during the day (data not shown), and that this correlated with a significant increase in hours slept during this period (Fig. 6J).

Metabolic cage analysis of DT-treated males revealed significant reductions in energy expenditure as was observed in females (Fig. 7A). Resting EE (Fig. 7B) and active EE were significantly lower (Fig. 7C) again, suggesting that the reductions in EE noted were independent of activity. No differences in overall respiratory quotient (Fig. 7D) or food consumption were observed (Fig. 7E); however, DT-treated males, much like females, consumed significantly less water than controls (Fig. 7F). DT-treated males, unlike females, exhibited no differences in wheel activity (Fig. 7G,H) or hours at rest (Fig. 7I,J). Importantly, the reductions in metabolism noted with DT treatment in OCN-Cre;iDTR mice were not observed in DT-treated C57BL/6J males (Supplementary Fig. S6), supporting previous studies that the administration of DT has no effect on normal mice. We hypothesize that weight loss in the presence of reduced energy expenditure, with no significant differences in food intake, could be, in part, caused by reduced circulating SOST (based on data by Kim and colleagues),(22) which we detected after 1 week of DT treatment in a separate, smaller cohort of male mice by serum ELISA (Supplementary Fig. S7A) and SOST immunohistochemistry of femoral histological sections (Supplementary Fig. S7B, C). Importantly these data further show that the metabolic phenotypes observed were specifically caused by bone cell depletion, implicating bone cells in the maintenance of normal energy metabolism.

Discussion

In this study, we used the OCN-Cre;iDTR model to deplete OCN+ cells (chondrocytes, OBs, and osteocytes) during a critical window of longitudinal growth. We observed sexually dimorphic bone phenotypes and decreased energy expenditure in both sexes in response to DT treatment. Interpreting such widespread complex changes in response to targeting OCN+ cells, underlines one of the limitations of this model, which includes targeting multiple cell types, making it difficult to speculate on a single mechanism driving our phenotypes. Nevertheless, our findings build on previously published work and further highlight bone as an endocrine organ.
Our results suggest that depletion of OCN+ cells with 2 weeks of DT treatment results in significantly reduced bone in young female mice through inhibiting bone formation, with no effect on resorption, consistent with Corral and colleagues.\(^\text{(23)}\) However, in males we observed no significant changes in bone parameters as measured by \(\mu\)CT, although further examination revealed expansion of unmineralized cartilage adjacent to the growth plate and a mineralized matrix tissue within the primary spongiosa. This response in females was similar to that seen in an osteocyte-specific ablation model driven by a dentin matrix...
protein 1 promoter, which showed long-term osteocyte deficiency resulted in substantial trabecular bone loss, as well as changes to trabecular microstructure.24

Surprisingly, the phenotype that we observed in male DT-treated mice most closely resembled a number of conditional KO models for RANKL.25 Similar to what we observed, Xiong and colleagues found that when RANKL was deleted via OCN-Cre in 5-week-old mice, expansion of the primary spongiosa and growth plates, as well as clubbing in the distal femur was observed. Moreover, osteocyte-specific deletion of RANKL in adult mice led to an increase in bone mass,25 suggesting that osteocyte-derived RANKL is responsible for the regulation of resorption and may contribute to the reduced cortical porosity that we observed in both sexes in our study. Although circulating RANKL was not significantly different in our male DT-treated mice, it is possible that lower local concentrations of RANKL were sufficient at the growth plate; hence, we believe the lack of RANKL remains a likely driver of the phenotypes we observed and requires further characterization.

The male DT-treated mice had, to our surprise, an expansion of cartilage-producing hypertrophic chondrocytes. It was once believed that terminally differentiated chondrocytes underwent apoptosis; however, previous studies have shown that during early-stage development hypertrophic chondrocytes can transdifferentiate into OBs.26 These transdifferentiated OBs makeup a substantial proportion of the bone-forming cells in mice.26

During late embryonic development and postnatal growth, mature chondrocytes maintain their ability to become OBs.26 Even at the late growth period of 11 weeks, chondrocytes contribute to the osteoblast pool within the primary spongiosa,26 and chondrocyte-derived OBs also repair trabecular bone after insult, similar to developmental endochondral ossification involving a cartilage intermediate.23,27 Thus, we propose that the increased safranin O staining and chondrocyte presence in males were a recovery response to the damage induced through the depletion of OCN+ cells.

In the growth plate, chondrocytes form columns that direct bone lengthening, a process that is driven by the rate of transition from proliferating chondrocytes to hypertrophic chondrocytes.26 In OCN-Cre;iDTR mice, vehicle-treated males exhibited relatively normal chondrocyte organization—with round

Table 2. Top 10 Differentially Expressed Proteins in DT-Treated Sera as Assessed by Proteomic Analysis

| Dysregulated proteins | p Value | FC |
|-----------------------|---------|----|
| Extracellular matrix protein 1 H3 | 3.42E-07 | 3.62 |
| Inter-alpha-trypsin inhibitor heavy chain | 3.68E-07 | 2.25 |
| Clusterin | 4.44E-06 | 2.22 |
| Zinc-alpha-2-glycoprotein O | 1.45E-05 | 3.69 |
| Serine protease inhibitor A3M | 2.73E-05 | 3.07 |
| Gelsolin | 1.52E-08 | 0.46 |
| Patatin-like phospholipase domain-containing protein 2 | .00024 | 0.40 |
| Complement factor D | .00076 | 0.37 |
| Very long-chain specific acyl-CoA dehydrogenase, mitochondrial | .00111 | 0.36 |
| ADP-ribosylation factor GTPase-activating protein 3 | .00168 | 0.37 |

DT = Diphtheria toxin; FC = ________.

“reserve” chondrocytes at the top of the growth plate—and clear columns of embedded chondrocytes at the growth plate. In DT-treated males, but not females, we observed disorganized chondrocytes without clear columns and an expansion of the proliferative zone. We speculate that removal of bone-forming cells during this critical developmental window creates this sexually dimorphic phenotype through a number of connected and complex mechanisms.

We are unsure what causes the sexual dimorphism we observed, but it is possible that during this period, elevated estrogen levels in females contribute to the restriction of the chondrocyte proliferative zone via ERα signaling.1,2 Relatedly, androgen receptor (AR) mRNA has also been detected in proliferating and early hypertrophic chondrocytes in the growth plate of male and female rats, with males exhibiting higher AR mRNA and nuclear AR protein compared with females during sexual maturation.28 Combined, these studies indicate that chondrocytes are directly regulated by sex steroid hormones, which would be at their peak elevations during our DT-treatment window. Additionally, growth hormone and IGF-1 are heavily involved in postnatal growth and exhibit crosstalk with sex steroids during puberty. IGF-1, which is higher in males than females during puberty, appears to be the primary determinant of skeletal sexual dimorphism, and likely interacts with both estrogens and androgens to elicit even greater differences in phenotype.1,2

In the OCN-Cre/igf1fl/flfox, it was reported that abnormalities described... were qualitatively similar, but less pronounced in male experimental animals (data not shown),29 suggesting that these mice may also have shown sexual dimorphism in response to removal of the IGF-1 receptor on OCN+ cells. On the other hand, the phenotype we observed may be independent of sex hormones or insulin based on the work by Goring and colleagues, who found that conditional disruption of VEGF in OCN-expressing cells in mice exerts a divergent influence on morphological, cellular, and whole-bone properties between sexes; furthermore, they describe that the underlying sexual divergence in VEGF signaling in osteoblast cultures in vitro is independent of circulating sex hormones.10 Thus, it remains to be determined why we saw such differences between male and female bone phenotypes in response to ablation of OCN+ cells.

Prior publications describing the OCN-Cre;iDTR mice have focused primarily on the important link between the skeleton and immune function. By specifically deleting OCN+ bone cells, these studies found defects in T-cell lymphopoiesis10 and suppressed neutrophil response,11 along with a marked reduction in bone parameters. Work by Yu and colleagues used 4-week-old mice and found significantly reduced body size and body weight after 2 weeks of DT treatment, coupled with a decrease in bone volume, which is consistent with our results in females.10 These two prior studies did not examine or report on sexually dimorphic responses or any effects on chondrocytes.

DT-treated mice exhibited changes in their blood sera lipid and protein profiles. In both males and females, there was a highly significant—nearly fourfold—increase in ECM1, which is expressed in many tissues including chondrocytes, and has been shown to regulate endochondral bone formation20 and angiogenesis.31 Overexpression of ECM1 via tissue-specific transgene expression indicates that it inhibits both osteoblast and chondrocyte function; reduced bone parameters are seen in osteoblast-specific overexpression models and growth plate abnormalities are seen in transgenic mice with chondrocyte-specific overexpression.20 Future studies should examine
whether elevated serum ECM1 contributes to the bone phenotypes we observed. Serum proteomics analysis also revealed that proteins involved in critical processes were aberrantly expressed upon depletion of bone cells (Fig. 5C), which lends strength to our finding that disrupting endochondral bone formation in developing mice has substantial effects on homeostasis.

OCN+ cell ablation also induced a few changes that were detectable in a standard blood chemistry panel including elevated CPK and ALT. CPK is a muscular enzyme that can be used to determine muscle deterioration or reduced muscular activity, and changes in CPK could support recent findings that bone and muscle exhibit crosstalk via OCN and RANKL.\(^\text{32}\) In particular,
OCN has been characterized as a key regulator of muscle mass and exercise adaptation. However, much of the prior research was performed with only one sex, or the sex of the mice was not described, which may explain why the sexual dimorphism of OCN removal or OCN+ cell ablation was not described before. Female DT-treated mice also showed an elevation of the liver enzyme ALT. Elevation of ALT could be coupled with the significant weight loss we observed because no other liver enzymes in the females were affected. Lack of additional significant findings in the full blood chemistry panel strengthens the specificity of the targeted ablation of bone cells as others have reported, because no signs of organ damage were detected.

Here, we demonstrate that targeting bone cells has an effect on animal metabolism and overall health. Our metabolic cage analyses revealed significantly decreased energy expenditure in both sexes following DT treatment. By targeting OCN+ cells, DT treatment is likely altering OBs and osteocytes, which secrete.

**Figure 7.** Diphtheria toxin (DT) male mice had decreased energy expenditure (EE). Metabolic cage analysis following 1-week DT treatment of 6-week-old male mice (n = 6–7 males per group). (A) Average energy expenditure (kcal/h), (B) resting energy expenditure (REE; kcal/30 min), (C) active energy expenditure (AEE; kcal/15 min), (D) respiratory quotient (RQ; %), (E) food consumption (g/24 h), (F) water consumption (g/day), (G) wheel distance (m) measured at walk or run, (H) wheel speed (m/s). Twelve-hour-cycle data for time spent sleeping (h) in the day (I) and night (J). *p < .05; **p < .01; ***p < .001; ****p < .001 versus vehicle. Data shown as individual dot plots ± SD. All analyses were performed as a Student’s t test with GraphPad Prism.
additional hormones involved in the control of energy metabolism. \cite{34-35} This could explain the complex metabolic changes observed in our model. Depletion of OCN alone, the osteoblast-derived hormone that signals to various organs throughout the body and plays a role in multiple energy-related processes, \cite{10,7,9} likely contributes to the reduced energy expenditure phenotype we observed. Overall, our data support the notion that OCN+ cells are crucial regulators of whole-body energy metabolism and bone-building activities during development, and that removal of these cells and their signaling factors has different effects based on the organism’s sex.

Acknowledgments

Funding for this work was supplied by the National Institutes of Health: grant no. R37CA245330 to Dr Reagan, and grant nos. P30GM106391, P30GM103392, P20GM121301, and U54GM115516, which support the Proteomics and Lipidomics, Molecular Phenotyping, Physiology, and Professional Development Cores. The authors’ work is also supported by a pilot grant from the MGH Center for Skeletal Research (NIH/NIAMS P30 AR066261), the American Cancer Society (RSG-19-037-01-LIB and IRG-16-191-33; Dr Reagan, Principal Investigator), the Canadian Institutes of Health Research (PJ-T-159534; Dr Ferron, Principal Investigator), the Kane Foundation, and Harvard’s Center for Skeletal Research (NIH/NIAMS P30AR075042). The authors would like to thank Dr David Scadden and Dr Irene Gobrial for providing founders for the OCN-Cre;iDTR mouse line. The authors would also like to thank Dr Carolyne Falank, Dr Clifford Rosen, Dr Mary Bouxsein, Dr Daniel Brooks, and Mariah Farrell for their valuable contributions to the progression of this project. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author Contributions

Heather Fairfield: Conceptualization; data curation; formal analysis; investigation; methodology; project administration; resources; software; supervision; validation; visualization; writing-original draft; writing-review and editing. Samantha Costa: Data curation; investigation; methodology; resources; writing-original draft; writing-review and editing. Victoria DeMambro: Data curation; formal analysis; investigation; software; writing-original draft; writing-review and editing. Celine Schott: Formal analysis; methodology; resources; writing-review and editing. Janaina Martins: Formal analysis; methodology; visualization; writing-review and editing. Mathieu Ferron: Conceptualization; data curation; funding acquisition; investigation; methodology; resources; supervision. Calvin Vary: Data curation; investigation; methodology; resources; software; validation; visualization; writing-original draft; writing-review and editing.

Authors’ roles

Study design: HF and MR. Study conduct: HF, SC, and MR. Data collection: MR, HF, SC, and JM. Data analysis: HF, SC, JM, and MR. Metabolic cage experiments: VD. Data interpretation: MR, CV, HF, VD, SC, CS, and MF. Serum analyses: HF, SC, CV, CS, and MF. Drafting manuscript: HF, SC, and MR. Revising manuscript content: HF, SC, VD, MF, and MR. Approving final version of manuscript: MR, HF, CV, SC, CS, MF, and JM. MR takes responsibility for the integrity of the data analysis.

References

1. Callewaert F, Sinnesael M, Gielen E, Boonen S, Vanderschueren D. Skeletal sexual dimorphism: relative contribution of sex steroids, GH-IGF1 and mechanical loading. J Endocrinol. 2010;207(2):127–34.
2. Callewaert F, Venken K, Kopchick JJ, et al. Sexual dimorphism in cortical bone size and strength but not density is determined by independent and time-specific actions of sex steroids and IGF-1: evidence from pubertal mouse models. J Bone Miner Res. 2010;25(3):167–26.
3. Öz OK, Zenewich JE, Fisher C, et al. Bone has a sexually dimorphic response to aromatase deficiency. J Bone Miner Res. 2010;15(3):507–14.
4. Kronenberg HM. Developmental regulation of the growth plate. Nature. 2003;423(6937):332–6.
5. Manolagas SC, O’Brien CA, Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013;9(12):699–712.
6. Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. Nature. 2012;481(7381):314–20.
7. Mera P, Laue K, Ferron M, et al. Osteocalcin signaling in myoblasts is necessary and sufficient for optimum adaptation to exercise. Cell Metab. 2016;23(6):1078–92.
8. Oury F, Khirmian L, Denny CA, et al. Maternal and offspring pools of osteocalcin influence brain development and functions. Cell. 2013;155(1):228–41.
9. Oury F, Ferron M, Huizhen W, et al. Osteocalcin regulates murine and human fertility through a pancreas-bone-testis axis. J Clin Invest. 2013;123(6):2421.
10. Yu WVC, Saez B, Cook C, et al. Specific bone cells produce DLL4 to generate thymus-seeding progenitors from bone marrow. J Exp Med. 2015;212(5):759–74.
11. Engblom C, Pfirsich C, Zilionis R, Da Silva Martins J, Bos SA, Courties G, et al. Osteoblasts remotely supply lung tumors with cancer-promoting SiglecF high neutrophils. Science. 2017;358(6367):eaal5081.
12. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res. 2013;28(1):2–17.
13. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010;25(7):1468–86.
14. Bornstein S, Moschetta M, Kawano Y, et al. Metformin affects cortical bone mass and marrow adiposity in diet-induced obesity in male mice. Endocrinology. 2017;158(10):3369–85.
15. Scheller EL, Troiano N, Vanhoutan JN, et al. Use of osmium tetroxide staining with microcomputed tomography to visualize and quantify bone marrow adipose tissue in vivo. Methods Enzymol. 2014;537:123–39.
16. Scheller EL, Troiano N, Vanhoutan JN, et al. Use of osmium tetroxide staining with microcomputed tomography to visualize and quantify bone marrow adipose tissue in vivo. Methods Enzymol. 2014;537:123–39.
17. Ivosev G, Burton L, Bonner R. Dimensionality reduction and visualization in principal component analysis. Anal Chem. 2008;80(13):4933–44.
18. Mera P, Laue K, Wei J, Berger JM, Karsenty G. Osteocalcin is necessary and sufficient to maintain muscle mass in older mice. Mol Metab. 2016;5(10):1042–7.
19. Gomes SA, Dos Reis LM, De Oliveira IB, Noronha IDL, Jorgetti V, Heilberg IP. Usefulness of a quick decalcification of bone sections embedded in methyl methacrylate: an improved method for immuno-histochemistry. J Bone Miner Metab. 2008;26(1):110–3.
20. DeMambro VE, Le PT, Guntur AR, et al. Igfbp2 deletion in ovariectomized mice enhances energy expenditure but accelerates bone loss. Endocrinology. 2015;156(11):4129–40.
21. Kim SP, Frey JL, Li Z, et al. Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes. Proc Natl Acad Sci U S A. 2017;114(52):E11238–47.

22. Schindeler A, McDonald MM, Bokko P, Little DG. Bone remodeling during fracture repair: the cellular picture. Semin Cell Dev Biol. 2008 Oct;19(5):459–66.

23. Tatsumi S, Ishii K, Amizuka N, et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 2007;5(6):464–75.

24. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O’Brien CA. Matrix-embedded cells control osteoclast formation. Supplementary methods. Nat Med. 2011;17(10):1235–41.

25. Zhou X, von der Mark K, Henry S, Norton W, Adams H, de Crombrugge B. Chondrocytes transdifferentiate into osteoblasts in endochondral bone during development, postnatal growth and fracture healing in mice. PLoS Genet. 2014 Dec 4;10(12):e1004820.

26. Gerstenfeld LC, Cullinane DM, Barnes GL, Graves DT, Einhorn TA. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem. 2003;88 (5):873–84.

27. van der Eerden BCJ, van Til NP, Brinkmann AO, Lowik CWGM, Wit JM, Karperien M. Gender differences in expression of androgen receptor in tibial growth plate and metaphyseal bone of the rat. Bone. 2002 Jun;30(6):891–6.

28. Zhang M, Xuan S, Bouxsein ML, et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem. 2002;277(46):44005–12.

29. Kong L, Zhao Y-P, Tian Q-Y, et al. Extracellular matrix protein 1, a direct targeting molecule of parathyroid hormone-related peptide, negatively regulates chondrogenesis and endochondral ossification via associating with progranulin growth factor. FASEB J. 2016;30(8):2741–54.

30. Han Z, Ni J, Smits P, et al. Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells. FASEB J. 2001;15(6):988–94.

31. Bonewald L. Use it or lose it to age: a review of bone and muscle communication. Bone. 2019;120:212–8.

32. Miyamoto T, Oguma Y, Sato Y, et al. Elevated creatine kinase and lactic acid dehydrogenase and decreased osteocalcin and Uncarboxylated osteocalcin are associated with bone stress injuries in young female athletes. Sci Rep. 2018 Dec 21;8(1):18019.

33. Jansson JO, Palsdottir V, Hägg DA, et al. Body weight homeostat that regulates fat mass independently of leptin in rats and mice. Proc Natl Acad Sci U S A. 2017;115(2):427–32.

34. AI RO, Chow J, Lacombe J, et al. Proprotein convertase furin regulates osteocalcin and bone endocrine function. J Clin Invest. 2017;127(11):4104–17.

35. Yoshikawa Y, Kode A, Xu L, et al. Genetic evidence points to an osteocalcin-independent influence of osteoblasts on energy metabolism. J Bone Miner Res. 2011;26(9):2012–25.